Skip to main content
  • Letter to the Editor
  • Open access
  • Published:

CD44 promotes hepatocellular carcinoma progression via upregulation of YAP

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy in human. CD44 is a transmembrane glycoprotein which is frequently overexpressed in cancer of various origins. The function and mechanism of CD44 in HCC remains elusive. In this study, we reported that CD44 was overexpressed in HCC to promote the proliferation and migration of HCC cells via oncogenic YAP, which is the key downstream regulator in Hippo pathway. These findings suggest that CD44-YAP is a probable important axis in pathogenesis of HCC, providing an insight in to HCC pathogenesis as well as potential targets for the intervention of HCC.

Main text

Metastasis and recurrence frequently occur after surgical removal in patients with hepatocellular carcinoma (HCC) [1]. Better understanding on the molecular mechanism behind HCC pathogenesis is required for further development of new therapeutic approaches. CD44 is a multistructural and multifunctional transmembrane glycoprotein [2]. Accumulating evidences reveal dysregulation of CD44 in many types of cancer [3,4,5]. In this study, we intended to investigate the function and mechanism of CD44 in HCC.

To investigate this, first, we analyzed the expression profile in HCC based on the TCGA database. We found that CD44 expression level was elevated in tumor compared to normal tissues and HCC patients with higher CD44 expression show worse prognosis compared to those with lower CD44 expression (Additional file 1: Fig. S1A, Fig. 1A). In a set of HCC cells lines, SMMC-7721 and MHCC-97 H cells showed high endogenous CD44 expression, while the expression of CD44 in PLC and Huh7 cells was undetectable (Additional file 1: Fig. S1B). To ascertain the role of CD44 in HCC, we silenced CD44 using small interfering RNAs in SMMC-7721 and MHCC-97 H cells, and found that depletion of CD44 significantly inhibited cell proliferation, colony formation, migration and invasion of SMMC-7721 and MHCC-97 H cells (Additional file 1: Fig. 1B–F, Additional file 1: Fig. S1C, D). In agreement with this, ectopic overexpression of CD44 in PLC and Huh7 cells accelerated cell proliferation and enhanced colony forming, migration and invasion ability of cells (Additional file 1: Figs. S1E, S2A–E).

Fig. 1
figure 1

Loss of CD44 inhibited HCC progression. A Kaplan–Meier curves show the overall survival of patients with high or low expression of CD44 in HCC. Statistical significance was determined by a log-rank test. B Cell viability was measured in SMMC-7721 and MHCC-97 H cells with CD44 knockdown using siRNAs, and the CCK8 assay was performed to analyze cell proliferation. CF The colony formation assay, wound-healing, migration and invasion assay were performed in SMMC-7721 and MHCC-97 H cells with CD44 depletion. All data are the mean ± SD, n = 3, t-test, *P < 0.05, **P < 0.01, ***P < 0.001

Hippo pathway with oncogenic yes-associated protein (YAP) as the key downstream factor was documented to play an important role in various cancers including HCC via translocating from cytoplasm into nucleus for transcription activation of a set of oncogenic genes [6,7,8]. We found that YAP protein level was positively regulated by CD44 (Fig. 2A). Additionally, immunofluorescence showed that CD44 silencing led to translocation of YAP from nucleus to cytoplasm (Fig. 2B). Furthermore, when we overexpressed YAP in CD44-depleted HCC cells, we observed that cell proliferation and invasion ability were restored (Fig. 2C–G). These findings suggest that CD44 promoted HCC progression via YAP.

Fig. 2
figure 2

CD44 facilitated HCC progression via regulating Hippo-YAP signaling. A Overexpression or knockdown of CD44 in HCC cells, lysates were prepared and blotted with the indicated antibodies. B The cellular localization of YAP protein was determined by immunofluorescence in MHCC-97 H cells transfected with CD44 siRNAs, Scale bar represent 20 μm. C Representative western blots showed that over-expression of YAP in SMMC-7721 cells with CD44 knockdown. D–F Cell viability, wound-healing assay and invasion assay were performed on CD44-depleted SMMC-7721 cells with YAP overexpression, scaled bars represent 400 μm. G Quantification of the invaded cells in (F). All data are the mean ± SD, n = 3, t-test,*P < 0.05, ***P < 0.001

In summary, we demonstrate that overexpression of CD44 promotes HCC progression via YAP. Although loco-regional therapy and systemic chemotherapy are widely used for HCC efficacious treatment, many obstacles still exist for treatment of HCC, in which the most common is drug resistance and recurrence. Therefore, the oncogenic CD44-YAP axis in HCC revealed here can be a potential target for the intervention of HCC.

Availability of data and materials

All data generated or analyzed during this study are included in this article are available from the corresponding author on reasonable request.

Abbreviations

HCC:

Hepatocellular carcinoma

YAP:

Yes-associated protein

References

  1. Ge Y, Mu W, Ba Q, Li J, Jiang Y, Xia Q, et al. Hepatocellular carcinoma-derived exosomes in organotropic metastasis, recurrence and early diagnosis application. Cancer Lett. 2020;1:41–8.

    Article  Google Scholar 

  2. Shirasaki T, Honda M, Yamashita T, Nio K, Shimakami T, Shimizu R, et al. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Sci Rep. 2018;3(1):13143.

    Article  Google Scholar 

  3. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;10(1):64.

    Article  CAS  Google Scholar 

  4. Ryu D, Ryoo IG, Kwak MK. Overexpression of CD44 standard isoform upregulates HIF-1alpha signaling in hypoxic breast cancer cells. Biomol Ther. 2018;26(5):487–93.

    Article  CAS  Google Scholar 

  5. Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020;10(1):36.

    Article  Google Scholar 

  6. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23(7):785–93.

    Article  CAS  Google Scholar 

  7. Shin E, Kim J. The potential role of YAP in head and neck squamous cell carcinoma. Exp Mol Med. 2020;52(8):1264–74.

    Article  CAS  Google Scholar 

  8. Yang Y, Li X, Wang T, Guo Q, Xi T, Zheng L. Emerging agents that target signaling pathways in cancer stem cells. J Hematol Oncol. 2020;26(1):60.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Zhi Xu for the technical help.

Funding

This work was supported by “Transformation Medicine Cross Research Fund” (Grant No.: ZH2018QNB25 to W. Zhao), the National Natural Science Foundation of China (Grant No.: 81974447 & 81572712 to L. Chen), the Natural Science Fund for Distinguished Young Scholars of Jiangsu Province (Grant No. : BK20200035 to L. Chen), and the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization, LC; Methodology, LC, SY, JZ, ZM, HZ, WZ, XH, JW; Investigation, SY, JZ, ZM, HZ, WZ., TT, XH, JW; Resources, LC; Writing: LC, JZ; Supervision, LC; Project Administration, LC. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Shiyi Yu, Weiyong Zhao or Liming Chen.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

CD44 promotes hepatocellular carcinoma progression via upregulation of YAP.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, J., He, X., Wan, Y. et al. CD44 promotes hepatocellular carcinoma progression via upregulation of YAP. Exp Hematol Oncol 10, 54 (2021). https://doi.org/10.1186/s40164-021-00247-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40164-021-00247-w

Keywords